Equities
Ming Yang Smart Energy to slash registered capital by 3.1% via share cancellation
Chinese wind-turbine maker cancels over 70 million A-shares from prior buyback, reducing registered capital from RMB2.26bn to RMB2.19bn after board approval.
EYDAP Reports H1 2026: Growth Plans, Execution Delays and €2.8B Investment Push
Athens water utility EYDAP outlines H1 2026 financials, including €17m revenue growth and a €2.8bn investment program, amid delays in peripheral utility consolidation and water service expansion.
Vicore Pharma outlines buloxibutid trial data, cash runway ahead of mid‑2027 readout
At a Stifel virtual forum, Vicore Pharma presented Phase II results for its oral AT2‑receptor agonist, highlighted a $93 million cash position lasting into late 2028 and noted a pre‑market share price of $9.61.
AtlasClear Posts Strong Q4 2026 Revenue Beat, Shares Surge 38%
Fiscal 2026 revenue grew 85% to $20.1 million, driven by non-commission revenue growth and strategic correspondent broker-dealer expansion.
EQB Reports Growth Amid Credit Strain at CIBC Conference
EQB Inc. shares rose 22% YTD, 36% over past year, as it navigates housing backdrop and credit card risks.
Shearwater Group Plans Shareholder Vote on £19.9M Capital Reduction
The company seeks shareholder approval for a special resolution to cancel deferred shares and amend articles, requiring 75% support and court confirmation before implementation.
C4 Therapeutics Shows Immune Activation in Multiple Myeloma Trials with Cemsidomide
Biomarker data from Phase 1 trials highlights T-cell activation and safety at tested doses, advancing Phase 1b studies with elranatamab combination.
Core Scientific Names Jay Elms as CCO to Boost AI Data Center Sales
The Miami-based colocation provider expands its commercial leadership with a veteran from data center sales, targeting AI workloads and hyperscale clients.
CoreCivic Names Mayberry as CEO After Swindle Resigns Due to Health
CoreCivic, Inc. appointed Lucibeth N. Mayberry as CEO following Patrick D. Swindle’s resignation amid stage-four pancreatic cancer treatment.
Sellas Reports Preclinical Evidence for CDK9 Inhibitor SLS009 in Pancreatic Cancer
Sellas Life Sciences Group Inc. highlighted encouraging preclinical data for its CDK9 inhibitor SLS009, showing potential synergy with RAS-directed therapies in MYC-amplified pancreatic cancer models.
Bernstein Names Sonova, Alcon Top European Medtech Picks for H2
The firm highlighted Sonova as its short-term top pick and Alcon as the preferred long-term play, citing strong fundamentals in hearing aids and ophthalmology.
Leader's Advantage SPAC raises $150M in Nasdaq IPO
The SPAC completes a $150 million initial public offering on Nasdaq with units priced at $10 each, targeting healthcare, specialty chemicals, and defense sectors.
FMC Stock Hits 52-Week Low at $9.48 Amid Revenue Miss and Demand Headwinds
Ag-chemical maker FMC saw shares fall to $9.48, down 70% over the past year, after Q2 results showed a revenue shortfall driven by weak demand and pricing pressure.
Together Housing Pushes Back Audited Accounts to Oct. 26
Issuer of £350m secured bonds cites complex legal settlement as the reason for the delay beyond the 180-day regulatory window.
Coursera Shares Sink to 52-Week Low as Analysts See Upside
Coursera stock dropped to $4.98, nearly 60% below its 52-week high, despite strong second-quarter results and analyst upgrades driven by Udemy integration progress.
Canopy Growth Postpones Shareholder Meeting Until Oct. 23 Over Quorum Shortfall
Canopy Growth adjourned its annual meeting after failing to meet the 33 1/3% quorum threshold; the vote will reconvene Oct. 23 via webcast.
Veon Stock Surges to 52-Week High on Strong Digital Growth and Raised Guidance
Veon shares climbed to $74.60, up nearly 49% over six months, as the telecom operator raised its 2026 revenue and EBITDA outlook following a sharp second-quarter earnings beat.
Chip Stocks Extend AI-Driven Gains as Tech Picks Lead Market
AI-themed equity strategies posted monthly returns of 10% or more as semiconductor names rallied, extending outperformance against the S&P 500 that has persisted since late 2023.
ISS Backs Two ATG Capital Nominees for Empery Digital Board
Proxy advisory firm recommends shareholder support for ATG's board slate and withhold votes from two incumbent directors at Empery Digital's Oct. 14 annual meeting.
Moleculin Biotech Presents Preclinical Pancreatic Cancer Data at AACR
The company shared preclinical findings on its Annamycin candidate showing immune-mediated antitumor activity in pancreatic cancer, while its primary clinical program targets relapsed AML.
Turnium Technology raises up to C$3.5m via private placement, settles debt
Vancouver-based Turnium Technology plans a C$3.5 million non-brokered private placement and a C$2 million debt settlement under NI 45-106.
AllianceBernstein Names Onur Erzan as New CEO, Effective April 2027
Equitable Holdings selects former McKinsey executive to lead $919 billion asset manager as Bernstein steps down after a decade.
OneMedNet Announces 1-for-10 Reverse Stock Split for Nasdaq Listing Compliance
The company will reduce outstanding shares to meet Nasdaq’s minimum bid price requirement, effective September 29, 2026.
Newron Halts US Recruitment for Evenamide Phase-3 Study Amid FDA Pause
Swiss biopharma firm pauses US patient enrollment in schizophrenia trial after FDA confirms temporary hold following a participant’s death outside the U.S., while expanding global recruitment for the drug’s development.
